Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

NCT00735917 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: saracatinib
OTHER: pharmacogenomic studies
OTHER: pharmacological study
PROCEDURE: positron emission tomography
RADIATION: fludeoxyglucose F 18
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)